ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Zhang, Yang ^a,b   Sun, Yihua ^a,b   Li, Yuan ^a,b   Fang, Zhaoyuan ^c   Wang, Rui ^a,b   Pan, Yunjian ^a,b   Hu, Haichuan ^a,b   Luo, Xiaoyang ^a,b   Ye, Ting ^a,b   Li, Hang ^a,b   Wang, Lei ^a,b   Chen, Haiquan ^a,b   Ji, Hongbin ^c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c Chinese Academy of Sciences   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AAA NUCLEAR COREGULATOR CANCER ASSOCIATED PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; ATAD2 PROTEIN, HUMAN; DNA BINDING PROTEIN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; RAS PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE MUTATION; HAZARD RATIO; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG RESECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PROTEIN EXPRESSION; ADENOCARCINOMA; AGED; CANCER STAGING; ENZYME IMMUNOASSAY; FOLLOW UP; GENETICS; LUNG NEOPLASMS; METABOLISM; MORTALITY; MUTATION; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

ADENOCARCINOMA; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84892796689     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3027-1     Document Type: Article

References (13)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Al-Kattan K, Sepsas E, Fountain SW, Townsend ER. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 1997;12:380-4.
3. Zhu CQ, Shih W, Ling CH, Tsao MS. Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. J Clin Pathol. 2006;59:790-800.
4. Ciro M, Prosperini E, Quarto M, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69:8491-8.
5. Zou JX, Revenko AS, Li LB, Gemo AT, Chen HW. ANCCA, an estrogen-regulated AAA? ATPase coactivator for ERalpha, is required for coregulator occupancy and chromatin modification. Proc Natl Acad Sci USA. 2007;104:18067-72.
6. Zou JX, Guo L, Revenko AS, et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 2009;69:3339-46.
7. Caron C, Lestrat C, Marsal S, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010;29: 5171-81.
8. Fouret R, Laffaire J, Hofman P, et al. A comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma. Clin Cancer Res. 2012;18:5606-16.
9. Detre S, Saclani Jotti G, Dowsett M. A ''quickscore'' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol. 1995;48:876-8.
10. Wang R, Pan Y, Li C, et al. The use of quantitative real-time reverse transcriptase PCR for 50 and 30 portions of ALK transcripts to detect ALK rearrangements in lung cancers. Clin Cancer Res. 2012;18:4725-32.
11. Detterbeck FC, Boffa DJ, Tanoue LT. The new lung cancer staging system. Chest. 2009;136:260-71.
12. Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/ European Respiratory Society International multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol. 2011;6: 244-85.
13. Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA. 1982;247:2543-6.